Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

about

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Item

http://www.wikidata.org/entity/Q58738102

description

article

@en

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Association of antithyroglobul ...... sfunction induced by nivolumab

@en

Association of antithyroglobul ...... sfunction induced by nivolumab

@nl

type

Item

label

Association of antithyroglobul ...... sfunction induced by nivolumab

@en

Association of antithyroglobul ...... sfunction induced by nivolumab

@nl

prefLabel

Association of antithyroglobul ...... sfunction induced by nivolumab

@en

Association of antithyroglobul ...... sfunction induced by nivolumab

@nl

P1476

Association of antithyroglobul ...... sfunction induced by nivolumab

@en

P2093

Aya Kuchiba

http://www.w3.org/2001/XMLSchema#string

Hiroshi Arima

http://www.w3.org/2001/XMLSchema#string

Ken Ohashi

http://www.w3.org/2001/XMLSchema#string

Noboru Yamamoto

http://www.w3.org/2001/XMLSchema#string

Shigehisa Kitano

http://www.w3.org/2001/XMLSchema#string

Shintaro Iwama

http://www.w3.org/2001/XMLSchema#string

Shiro Kimbara

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

Pembrolizumab for the treatment of non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

P304

3583-3590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13800

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Yutaka Fujiwara

Naoya Yamazaki

Yuichiro Ohe

P577

2018-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30230649

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6215874

http://www.w3.org/2001/XMLSchema#string